NAVB
$1.05
Navidea Biopharmaceuticals
($.10)
(8.70%)
NAVB
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  ($0.09)
Revenue:  $0.30 Mil
Thursday
Feb 6
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when NAVB reports earnings?

Where is NAVB's stock price going from here?
Up
Flat
Down
Stock chart of NAVB
Analysts
Summary of analysts' recommendations for NAVB
Score
Grade
Pivots
Resistance
$1.27
$1.22
$1.14

$1.09

Support
$1.01
$0.96
$0.88
Tweet
Growth
Description
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents for diseases such as cancer and Alzheimer. The Company's radiopharmaceutical development programs include: Lymphoseek(R), AZD4694 and RIGScan(TM). Navidea Biopharmaceuticals, Inc., formerly Neoprobe Corporation, is headquartered in Dublin, Ohio.
Peers
Myriad GeneticsImmunomedicsCareDxQuidelMeridian BioscienceSurModics